Diabetes is a severe chronic disease that affects 422 million adults worldwide in 2014. It was
the fifth leading cause of mortality in the Philippines in 2019. The primary cause of death of
diabetic patients is due to cardiovascular disease. α-Glucosidase inhibitors (AGIs) are
known for their cardiovascular benefits because they prevent the postprandial glucose level
from increasing, which plays a significant role in the development of cardiovascular
diseases. The synthesis of AGIs is complex and requires a lot of steps. Thus, there is a need …